Introducing Beransa: A Groundbreaking Treatment for Arthritis in Dogs

Despite the growing demand for effective therapies, canine arthritis has experienced minimal progress in recent years. However, 2023 marks the emergence of a groundbreaking new treatment class that offers renewed hope for enhancing the quality of life for dogs afflicted with this condition.

As we navigate these exciting times, it’s crucial to remain grounded in reality – no single treatment will be universally successful for all dogs. Nevertheless, Beransa, a brand-new therapy, presents a promising opportunity for alleviating the pain associated with canine arthritis.

 

Introducing Beransa

Beransa, the commercial name for bedinvetmab (also known as Librela outside Australia), is designed to neutralize nerve growth factor (NGF), a protein implicated in pain perception. As a monoclonal antibody, Beransa has the potential to be highly specific to its target and effectively block the activity of this mediator of pain. In Australia, Beransa is officially registered for alleviating pain related to osteoarthritis in dogs.

 

Effectiveness and Speed of Action

While some dogs have experienced significant improvement within days of beginning treatment with Beransa, it is essential to consider the scientific evidence supporting its efficacy. A single placebo-controlled study conducted by the parent company, Zoetis, demonstrates that after one week, roughly one in six dogs show improvement. This figure increased to one in two after a month.

 

It is important to note that:

  1. Caregiver placebo effects can be substantial with arthritis treatments, so maintaining realistic expectations about its effectiveness for each patient is essential.

  2. Many dogs may need additional or alternative arthritis remedies in combination or in place of Beransa for optimal results.

Based on the study and anecdotal evidence, Beransa may be worth considering for suitable candidates.

Results seen above are not representative of all dogs on Beransa.

 

Dosage and Administration

Beransa is administered as a subcutaneous injection at a dose of 0.5 – 1 mg/kg, with the option for monthly repetition. It is generally recommended to try at least two doses before determining its effectiveness.

Safety Considerations As NGF is vital for fetal and juvenile development, Beransa should not be used in breeding, pregnant or lactating dogs, or dogs under 12 months of age.

 

Potential Human Health Risks

Pregnant women, those attempting to conceive, and breastfeeding women should exercise extreme caution to avoid accidental self-injection or needle stick injuries.

It is important to clarify that treated dogs pose no risk to humans.

 

Possible Side Effects

Although rare, injection site reactions, such as swelling and heat, may occur. Hypersensitivity reactions are also possible, though these seem more common with Solensia, the feline version of the drug. Monoclonal antibodies like Cytopoint, Beransa and Solensia appear much safer than traditional drugs like anti-inflammatories, as they require minimal metabolism or detoxification by the liver or kidneys. However, caution is still recommended in dogs with liver or kidney disease until further studies can confirming they are safe to use in in these patient groups.

Beransa seems safe for use with other drugs and during vaccination. The primary concern with using multiple treatments is that adverse effects may be challenging to attribute to a specific cause.

 

Cost of Beransa

In 2023, a single Beransa injection costs between $100 and $145, depending on the required size, which is comparable to higher-priced anti-inflammatory drugs. The injection needs to be administered each month.

 

While Beransa may not be a panacea for osteoarthritis, having an additional treatment option is a significant advantage. For some dogs, it can maintain their quality of life when other options fail or are deemed unsafe.

 

Despite advances in the field of canine arthritis treatment, we still have progress to make. Monoclonal antibodies represent a step forward and may grant us more quality time with our beloved senior dogs. Consult your veterinarian to determine if Beransa might be the right choice for your dog. By considering their unique circumstances, your vet can help you make an informed decision about whether this innovative treatment could provide the relief your canine companion needs. With the development of monoclonal antibodies such as Beransa, we are one step closer to improving the lives of dogs suffering from arthritis and, ultimately, enhancing the precious time they have remaining.

Leave a Reply

Your email address will not be published. Required fields are marked *